Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Medicsen

Explore full profile

Needle-free drug delivery platform based on sonophoresis (ultrasounds) to replace needles and cannulas in the transdermal delivery of large molecules

Madrid, SpainFounded 2014Biotech & Life Sciences
Valuation $5–10M Last recorded · 2022
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Medicsen and the history behind them.

About Medicsen

Medicsen is a biomedical company that has developed a needle-free smart patch for the painless delivery of drugs through the skin. This is achieved through the use of sonophoresis, a technology that uses ultrasound waves to temporarily and safely increase the permeability of the skin, allowing for the administration of macromolecular drugs such as insulin.

Read full description

The company's primary focus is on diabetes management, with the goal of creating a non-invasive artificial pancreas. This system would integrate data from wearable sensors and use predictive AI and algorithms to manage insulin delivery automatically. The smart patch is designed to be an intuitive and user-friendly device.

The company was founded by a team of engineers and doctors, including Dr. Eduardo W. Jorgensen, who serves as the CEO. The team's expertise in both medicine and technology has driven the development of this novel drug delivery system.

Medicsen's business model is centered on the development and commercialization of its smart patch technology. The company targets individuals with chronic diseases, particularly diabetes, who require regular injections. By offering a painless and convenient alternative to traditional needles, Medicsen aims to improve the quality of life for these patients.

The smart patch is a closed-circuit system that combines a wearable sensor, a predictive AI algorithm, and the needle-free drug delivery mechanism. This integrated approach allows for the intelligent and automated management of chronic conditions.

Source: Dealroom company data

At a glance

Founded
2014
Headquarters
Madrid, Spain
Sector
Biotech & Life Sciences

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Turn8
  • European Innovation Council
  • EIT Health
  • Government of Spain
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States5%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Medicsen on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Medicsen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.